Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A likely 50,000 veterans have undiagnosed hepatitis C, and 80% of baby boomers with HCV in four health care systems may also be undiagnosed.
Giving Viread (tenofovir) to pregnant women with hepatitis B seems to succeed in preventing transmission of the virus to their babies.
Faldaprevir, deleobuvir and PPI-668 showed high promise in curing genotype 1a of hepatitis C virus in early trial results.
Incivek added to interferon and ribavirin shortens the treatment duration and raises cure rates among gay, HIV-positive men with acute hepatit...
When treated with sofosbuvir and ribavirin before a liver transplant, two out of three people with hepatitis in a recent study averted viral r...
Sofosbuvir and ribavirin appear to better treat post-transplant cases of hepatitis C than the currently available therapies.
Sofosbuvir and ledipasvir plus either ribavirin or GS-9669 cured 100 percent of those with genotype 1 of hepatitis C with advanced liver disea...
Interim results of a Phase II study of the fixed-dose combo of sofosbuvir and ledipasvir have paved the way for a Phase III study of the hep C...
In 12 weeks, daclatasvir, asunaprevir and BMS-791325 cured 92 percent of treatment-naive people with genotypes 1a or 1b of hepatitis C virus
A 12-week regimen boasts high cure rates among those with the difficult-to-treat genotype 1 of the virus.
AbbVie’s interferon- and ribavirin-free combination therapy of ABT-450/r and ABT-267 cured 90 to 95 percent of people w/ genotype 1b of HCV
Gilead’s sofosbuvir boasted high cure rates when given in combination with ribavirin to those with genotype 2 or 3 of hepatitis C.
Sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus in a recent...
Simeprevir demonstrated greater efficacy than the current line of hepatitis C drugs among those with genotype and who had compensated liver d...
BMS has submitted for approval in Japan daclatasvir and asunaprevir as the world’s first interferon- and ribavirin-free hep C treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.